Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-01
2008-01-01
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266200, C514S230500, C514S230800, C544S092000, C544S283000, C546S198000, C546S200000, C546S201000
Reexamination Certificate
active
07314883
ABSTRACT:
The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I)
REFERENCES:
patent: 5869489 (1999-02-01), Shah et al.
patent: 6313097 (2001-11-01), Eberlein et al.
patent: 6344449 (2002-02-01), Rudolf et al.
patent: 6521609 (2003-02-01), Doods et al.
patent: 6552043 (2003-04-01), Patchett et al.
patent: 2001/0036946 (2001-11-01), Rudolf et al.
patent: 2003/0139417 (2003-07-01), Eberlein et al.
patent: 2003/0181462 (2003-09-01), Doods et al.
patent: 2003/0191068 (2003-10-01), Trunk et al.
patent: 2003/0212057 (2003-11-01), Rudolf et al.
patent: 2003/0236282 (2003-12-01), Hurnaus et al.
patent: 2004/0002495 (2004-01-01), Sher et al.
patent: 2004/0014679 (2004-01-01), Trunk et al.
patent: 2004/0076587 (2004-04-01), Kruss et al.
patent: 2004/0132716 (2004-07-01), Rudolf et al.
patent: 2004/0192729 (2004-09-01), Rudolf et al.
patent: 2004/0214819 (2004-10-01), Rudolf et al.
patent: 2004/0229861 (2004-11-01), Burgey et al.
patent: 2004/0248816 (2004-12-01), Doods et al.
patent: 2005/0032783 (2005-02-01), Doods et al.
patent: 2005/0065094 (2005-03-01), Davidai
patent: 2005/0153959 (2005-07-01), Luo et al.
patent: 2005/0215546 (2005-09-01), Hurnaus et al.
patent: 2005/0215576 (2005-09-01), Degnan et al.
patent: 2005/0227968 (2005-10-01), Lustenberger et al.
patent: 2005/0233980 (2005-10-01), Doods et al.
patent: 2005/0234054 (2005-10-01), Mueller et al.
patent: 2005/0234067 (2005-10-01), Mueller et al.
patent: 2005/0250763 (2005-11-01), Mueller et al.
patent: 2005/0256098 (2005-11-01), Burgey et al.
patent: 2005/0256099 (2005-11-01), Mueller et al.
patent: 2005/0272955 (2005-12-01), Zimmer et al.
patent: 2006/0094707 (2006-05-01), Chaturvedula et al.
patent: 2006/0122250 (2006-06-01), Chaturvedula et al.
patent: 2006/0229447 (2006-10-01), Chaturvedula et al.
patent: 2 387 613 (2001-05-01), None
patent: 2 503 455 (2005-04-01), None
patent: 1 227 090 (2002-07-01), None
patent: 1 323 709 (2003-07-01), None
patent: WO 97/09046 (1997-03-01), None
patent: WO 98/09630 (1998-03-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/44922 (1998-10-01), None
patent: WO 98/45285 (1998-10-01), None
patent: WO 98/56779 (1998-12-01), None
patent: WO 99/52875 (1999-10-01), None
patent: WO 00/18764 (2000-04-01), None
patent: WO 00/55154 (2000-09-01), None
patent: WO 01/32648 (2001-03-01), None
patent: WO 01/25228 (2001-04-01), None
patent: WO 01/32649 (2001-05-01), None
patent: WO 01/49676 (2001-07-01), None
patent: WO 02/10140 (2002-02-01), None
patent: WO 02/22563 (2002-03-01), None
patent: WO 03/027252 (2003-04-01), None
patent: WO 03/070753 (2003-08-01), None
patent: WO 03/076432 (2003-09-01), None
patent: WO2004/002960 (2004-01-01), None
patent: WO 2004/037810 (2004-05-01), None
patent: WO 2004/082602 (2004-09-01), None
patent: WO 2004/082605 (2004-09-01), None
patent: WO 2004/082678 (2004-09-01), None
patent: WO 2004/083187 (2004-09-01), None
patent: WO 2004/087649 (2004-10-01), None
patent: WO 2004/091514 (2004-10-01), None
patent: WO 2004/092166 (2004-10-01), None
patent: WO 2004/092168 (2004-10-01), None
patent: WO 2005/000807 (2005-01-01), None
patent: WO 2005/009962 (2005-02-01), None
patent: WO 2005/013894 (2005-02-01), None
patent: WO 2005/056550 (2005-06-01), None
patent: WO2005/065779 (2005-07-01), None
patent: WO 2005/072308 (2005-08-01), None
patent: WO2005/084672 (2005-09-01), None
patent: WO 2005/092880 (2005-10-01), None
patent: WO 2005/095383 (2005-10-01), None
patent: WO/2005/100343 (2005-10-01), None
patent: WO/2005/100352 (2005-10-01), None
patent: WO/2005/100360 (2005-10-01), None
patent: WO 2005/102322 (2005-11-01), None
patent: WO 2005/103037 (2005-11-01), None
patent: WO/2005/121078 (2005-12-01), None
patent: WO 2006/052378 (2006-05-01), None
patent: WO 2006/060678 (2006-06-01), None
U.S. Appl. No. 11/508,568, filed Aug. 23, 2006, Chaturvedula et al.
Amara, S.G., et al., “Alternate RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products”,Nature, 1982, 298:240-244.
Ashina, M., et al., “Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks”,Pain, 2000, 86(1-2):133-138.
Brain, S.D., et al., “CGRP receptors: a headache to study, but will antagonists prove therapeutic in migraine?”,TiPS, 2002, 23(2): 51-53.
Carlström, A.-S. and Frejd, T., “Palladium-Catalyzed Bis-coupling of Dihaloaromatics with 2-Amidoacrylates”,J. Org. Chem., 1991, 56: 1289-1293.
Carlström, A.-S. and Frejd, T., Palladium-Catalyzed Synthesis of Didehydroamino Acid Derivatives,Synthesis, 1989, 6, 414-418.
Chu, D.Q., et al., “The calcitonin gene-related peptide (CGRP) antagonist CGRP8-37 blocks vasodilation in inflamed rat skin: involvement of adrenomedullin in addition to CGRP,”Neuroscience Letters, 2001, 310:169-172.
De Vries, P., et al., “Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy,”European Journal of Pharmacology, 1999, 375: 61-74.
Doods, H., et al., “Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist,”British Journal of Pharmacology, 2000, 129: 420-423.
Dygos, J.H., “A Convenient Asymmetric Synthesis of the Unnatural Amino Acid 2,6-Dimethyl-L-tyrosine”,Synthesis, 1992, 741-743.
Edvinsson, L., “Calcitonin Gene-Related Peptide (CGRP) and the Pathophysiology of Headache”,CNS Drugs, 2001, 15(10):745-753.
Escott, K.J., et al., “Effect of a calcitonin gene-related peptide antagonist (CGRP8-37) on skin vasodilatation and oedema induced by stimulation of the rat saphenous nerve”,British Journal of Pharmacology, 1993, 110, 772-776.
Escott, et al., “Trigeminal ganglion stimulation increases facial skin blood flow in the rat: a major role for calcitonin gene-related peptide”,Brain Research, 1995, 669:93-99.
Evans, B.N. et al., “CGRP-RCP, a Novel Protein Required for Signal Transduction at Calcitonin Gene-related Peptide and Adrenomedullin Receptors”,J. Biol. Chem., 2000, 275(4): 31438-31443.
Gallai, V., et al., “Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally”,Cephalalgia, 1995;15: 384-390.
Goadsby, P.J., et al., “Vasoactive peptide release in the extracerebral circulation of humans during migraine headache”,Annals of Neurology, 1990, 28(2):183-187.
Grant, A.D., “Evidence of a role for NK1 and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear”,British Journal of Pharmacology, 2002, 135: 356-362.
Hall, J.M. and Brain, S.D., “Interaction of amylin with calcitonin gene-related peptide receptors in the microvasculature of the hamster cheek pouch in vivo,”British Journal of Pharmacology, 1999, 126: 280-284.
Hall, J.M., et al., “Interaction of human adrenomedullin 13-52 with calcitonin gene-related peptide receptors in the microvasculature of the rat and hamster,”British Journal of Pharmacology, 1995, 114: 592-597.
Juaneda, C. et al. “The molecular pharmacology of CGRP and related peptide receptor subtypes”,TiPS, 2000, 21: 432-438.
Lassen, L.H. et al. “CGRP may play a causative role in migraine”,Cephalagia, 2002, 22(1): 54-61.
Mallee, J.J., et al. “Receptor Activity-modifying Protein 1 Determines the Species Selectivity of Non-peptide CGRP Receptor Antagonist”,J. Biol. Chem., 2002, 277(16): 14294-14298.
McLatchie, L.M. et al., “RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like
Chaturvedula Prasad V.
Chen Ling
Civiello Rita
Degnan Andrew P.
Dubowchik Gene M.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Makujina Shah R.
LandOfFree
Anti-migraine treatments does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-migraine treatments, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-migraine treatments will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2773841